Withholding Recognized Effective Adjuvant Anti-Neoplastic Chemotherapy in a Setting with Known Highly Active Treatment for Recurrent Disease: A Case Report
A young woman presenting with an ovarian immature teratoma (stage IA, grade 2) demonstrates the dilemma associated with the decision to withhold adjuvant chemotherapy of documented clinical utility in a setting where highly effective treatment is available should the cancer ultimately recur.
| Hoofdauteur: | |
|---|---|
| Formaat: | Artikel |
| Taal: | English |
| Gepubliceerd in: |
Karger Publishers
2010-07-01
|
| Reeks: | Case Reports in Oncology |
| Onderwerpen: | |
| Online toegang: | http://www.karger.com/Article/FullText/318532 |